Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Sarcoma | 24 | 2022 | 215 | 4.080 |
Why?
|
Stomach Neoplasms | 12 | 2022 | 266 | 3.220 |
Why?
|
General Surgery | 8 | 2022 | 229 | 2.320 |
Why?
|
Pancreatic Neoplasms | 19 | 2020 | 645 | 2.040 |
Why?
|
Pancreaticoduodenectomy | 15 | 2020 | 81 | 2.030 |
Why?
|
Soft Tissue Neoplasms | 10 | 2022 | 127 | 1.590 |
Why?
|
Internship and Residency | 9 | 2022 | 1004 | 1.490 |
Why?
|
Retroperitoneal Neoplasms | 8 | 2021 | 43 | 1.450 |
Why?
|
Neoadjuvant Therapy | 10 | 2021 | 318 | 1.340 |
Why?
|
Surgical Procedures, Operative | 7 | 2021 | 182 | 1.310 |
Why?
|
Laparoscopy | 8 | 2022 | 754 | 1.290 |
Why?
|
Adenocarcinoma | 12 | 2021 | 1169 | 1.220 |
Why?
|
Extremities | 11 | 2022 | 167 | 1.200 |
Why?
|
Pancreatectomy | 6 | 2020 | 148 | 1.120 |
Why?
|
Neoplasm Recurrence, Local | 14 | 2021 | 1313 | 1.120 |
Why?
|
Pneumonia, Viral | 5 | 2020 | 316 | 1.040 |
Why?
|
Coronavirus Infections | 5 | 2020 | 301 | 1.030 |
Why?
|
Carcinoma, Pancreatic Ductal | 8 | 2020 | 108 | 0.980 |
Why?
|
Postoperative Complications | 13 | 2022 | 2207 | 0.960 |
Why?
|
Gastrectomy | 6 | 2022 | 68 | 0.930 |
Why?
|
Gastrointestinal Stromal Tumors | 3 | 2012 | 23 | 0.860 |
Why?
|
Education, Medical, Graduate | 5 | 2020 | 369 | 0.860 |
Why?
|
Neurilemmoma | 1 | 2021 | 34 | 0.780 |
Why?
|
Pancreatitis | 3 | 2012 | 87 | 0.770 |
Why?
|
Surgery Department, Hospital | 1 | 2020 | 42 | 0.730 |
Why?
|
Retrospective Studies | 40 | 2023 | 8489 | 0.710 |
Why?
|
Humans | 89 | 2023 | 86643 | 0.690 |
Why?
|
Pancreas | 2 | 2011 | 239 | 0.690 |
Why?
|
Middle Aged | 54 | 2022 | 25028 | 0.690 |
Why?
|
Geriatric Assessment | 3 | 2017 | 166 | 0.680 |
Why?
|
Male | 63 | 2022 | 40965 | 0.660 |
Why?
|
Critical Care | 3 | 2020 | 370 | 0.630 |
Why?
|
Precancerous Conditions | 2 | 2009 | 196 | 0.620 |
Why?
|
Whole Body Imaging | 1 | 2017 | 41 | 0.590 |
Why?
|
Body Composition | 1 | 2017 | 68 | 0.580 |
Why?
|
Aged | 42 | 2021 | 18415 | 0.570 |
Why?
|
Lymph Node Excision | 2 | 2010 | 217 | 0.570 |
Why?
|
Chemotherapy, Adjuvant | 9 | 2019 | 468 | 0.550 |
Why?
|
Hepatectomy | 5 | 2023 | 166 | 0.550 |
Why?
|
Tomography, X-Ray Computed | 7 | 2019 | 2601 | 0.540 |
Why?
|
Neuroendocrine Tumors | 4 | 2023 | 105 | 0.530 |
Why?
|
Prognosis | 15 | 2022 | 3679 | 0.510 |
Why?
|
Female | 57 | 2022 | 44532 | 0.500 |
Why?
|
Survival Rate | 16 | 2021 | 1863 | 0.500 |
Why?
|
Nomograms | 4 | 2022 | 28 | 0.490 |
Why?
|
United States | 27 | 2022 | 6672 | 0.490 |
Why?
|
Referral and Consultation | 1 | 2016 | 328 | 0.480 |
Why?
|
Bile Ducts, Intrahepatic | 3 | 2009 | 70 | 0.470 |
Why?
|
Peritoneal Lavage | 1 | 2013 | 10 | 0.460 |
Why?
|
Preoperative Care | 4 | 2021 | 397 | 0.460 |
Why?
|
Radiotherapy, Adjuvant | 6 | 2020 | 292 | 0.460 |
Why?
|
Cholangiocarcinoma | 3 | 2009 | 66 | 0.450 |
Why?
|
Torso | 4 | 2020 | 12 | 0.450 |
Why?
|
Bile Duct Neoplasms | 3 | 2009 | 79 | 0.450 |
Why?
|
Aged, 80 and over | 18 | 2021 | 6509 | 0.430 |
Why?
|
Pancreatic Fistula | 3 | 2020 | 16 | 0.420 |
Why?
|
Liver Neoplasms | 4 | 2023 | 736 | 0.420 |
Why?
|
Adenocarcinoma, Papillary | 2 | 2009 | 8 | 0.420 |
Why?
|
Margins of Excision | 6 | 2021 | 39 | 0.420 |
Why?
|
Neoplasm Staging | 8 | 2019 | 1939 | 0.410 |
Why?
|
Ampulla of Vater | 2 | 2014 | 22 | 0.400 |
Why?
|
Robotic Surgical Procedures | 3 | 2022 | 267 | 0.390 |
Why?
|
Follow-Up Studies | 13 | 2021 | 3640 | 0.380 |
Why?
|
Pancreatic Cyst | 1 | 2010 | 28 | 0.370 |
Why?
|
Prospective Studies | 8 | 2020 | 4213 | 0.360 |
Why?
|
Adult | 27 | 2021 | 25648 | 0.360 |
Why?
|
Piperazines | 2 | 2012 | 272 | 0.360 |
Why?
|
Mucor | 1 | 2009 | 3 | 0.360 |
Why?
|
Amphotericin B | 1 | 2009 | 34 | 0.360 |
Why?
|
Personnel Selection | 2 | 2020 | 59 | 0.360 |
Why?
|
Mucormycosis | 1 | 2009 | 14 | 0.360 |
Why?
|
Length of Stay | 6 | 2020 | 702 | 0.360 |
Why?
|
Digestive System Neoplasms | 1 | 2009 | 20 | 0.350 |
Why?
|
Triazoles | 1 | 2009 | 96 | 0.340 |
Why?
|
Antineoplastic Agents | 5 | 2020 | 2360 | 0.340 |
Why?
|
Pyrimidines | 2 | 2012 | 370 | 0.340 |
Why?
|
Antifungal Agents | 1 | 2009 | 117 | 0.340 |
Why?
|
Specialties, Surgical | 3 | 2020 | 64 | 0.340 |
Why?
|
Professional Autonomy | 2 | 2020 | 41 | 0.330 |
Why?
|
Esophageal Neoplasms | 3 | 2020 | 321 | 0.320 |
Why?
|
Guideline Adherence | 1 | 2010 | 223 | 0.320 |
Why?
|
Gastrointestinal Diseases | 1 | 2009 | 146 | 0.320 |
Why?
|
Treatment Outcome | 15 | 2023 | 7993 | 0.320 |
Why?
|
Surveys and Questionnaires | 2 | 2020 | 2501 | 0.310 |
Why?
|
Evidence-Based Medicine | 1 | 2010 | 429 | 0.300 |
Why?
|
Xanthomatosis | 1 | 2007 | 5 | 0.300 |
Why?
|
Betacoronavirus | 5 | 2020 | 258 | 0.300 |
Why?
|
Granuloma, Plasma Cell | 1 | 2007 | 9 | 0.300 |
Why?
|
Predictive Value of Tests | 6 | 2020 | 1673 | 0.300 |
Why?
|
Patient Selection | 2 | 2021 | 685 | 0.290 |
Why?
|
Sarcopenia | 2 | 2018 | 13 | 0.290 |
Why?
|
Orbital Diseases | 1 | 2007 | 21 | 0.290 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2022 | 865 | 0.280 |
Why?
|
Clinical Competence | 6 | 2022 | 751 | 0.280 |
Why?
|
Disease-Free Survival | 8 | 2021 | 1204 | 0.270 |
Why?
|
Faculty, Medical | 2 | 2020 | 178 | 0.260 |
Why?
|
Risk Assessment | 5 | 2019 | 2261 | 0.260 |
Why?
|
Survival Analysis | 8 | 2020 | 1538 | 0.250 |
Why?
|
Fellowships and Scholarships | 2 | 2020 | 108 | 0.250 |
Why?
|
Propensity Score | 6 | 2020 | 136 | 0.240 |
Why?
|
Pandemics | 5 | 2020 | 740 | 0.240 |
Why?
|
Kupffer Cells | 2 | 2001 | 13 | 0.240 |
Why?
|
Organizational Innovation | 2 | 2020 | 41 | 0.230 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2007 | 592 | 0.230 |
Why?
|
Carcinoma, Hepatocellular | 2 | 2018 | 384 | 0.230 |
Why?
|
Limb Salvage | 2 | 2020 | 33 | 0.230 |
Why?
|
Neoplasms, Connective and Soft Tissue | 1 | 2022 | 4 | 0.220 |
Why?
|
Practice Guidelines as Topic | 1 | 2010 | 1036 | 0.220 |
Why?
|
Chondrosarcoma | 1 | 2022 | 48 | 0.220 |
Why?
|
Biliary Tract Diseases | 1 | 2022 | 34 | 0.210 |
Why?
|
Databases, Factual | 7 | 2020 | 814 | 0.210 |
Why?
|
Liposarcoma | 1 | 2021 | 10 | 0.210 |
Why?
|
Metastasectomy | 1 | 2021 | 9 | 0.210 |
Why?
|
Chicago | 3 | 2020 | 1379 | 0.200 |
Why?
|
Arm | 1 | 2021 | 91 | 0.200 |
Why?
|
Leg | 1 | 2021 | 137 | 0.200 |
Why?
|
Professional Staff Committees | 1 | 2001 | 7 | 0.200 |
Why?
|
Catheter Ablation | 1 | 2023 | 233 | 0.200 |
Why?
|
Informed Consent | 2 | 2020 | 266 | 0.200 |
Why?
|
Educational Measurement | 3 | 2013 | 225 | 0.190 |
Why?
|
Risk Factors | 9 | 2022 | 5417 | 0.190 |
Why?
|
Macrophage Activation | 1 | 2001 | 46 | 0.190 |
Why?
|
Attitude of Health Personnel | 2 | 2020 | 636 | 0.190 |
Why?
|
Cholestasis | 1 | 2001 | 47 | 0.190 |
Why?
|
Neoplasm Grading | 5 | 2020 | 357 | 0.190 |
Why?
|
Human Experimentation | 1 | 2001 | 39 | 0.190 |
Why?
|
Cholestasis, Extrahepatic | 1 | 2000 | 4 | 0.190 |
Why?
|
Cystic Adenomatoid Malformation of Lung, Congenital | 1 | 2000 | 3 | 0.190 |
Why?
|
Bronchopulmonary Sequestration | 1 | 2000 | 4 | 0.190 |
Why?
|
Liver Regeneration | 1 | 2000 | 32 | 0.190 |
Why?
|
Education, Distance | 1 | 2020 | 25 | 0.180 |
Why?
|
Computer-Assisted Instruction | 1 | 2020 | 43 | 0.180 |
Why?
|
Leukocyte Count | 1 | 2020 | 220 | 0.180 |
Why?
|
Imatinib Mesylate | 2 | 2012 | 126 | 0.180 |
Why?
|
Surgical Oncology | 1 | 2020 | 27 | 0.180 |
Why?
|
Leiomyosarcoma | 1 | 2020 | 40 | 0.180 |
Why?
|
Parathyroid Glands | 1 | 1999 | 74 | 0.180 |
Why?
|
Prenatal Diagnosis | 1 | 2000 | 104 | 0.180 |
Why?
|
Liver Transplantation | 2 | 2018 | 1268 | 0.180 |
Why?
|
Workload | 1 | 2020 | 128 | 0.170 |
Why?
|
Benzamides | 2 | 2012 | 229 | 0.170 |
Why?
|
Parathyroidectomy | 1 | 1999 | 78 | 0.170 |
Why?
|
Program Evaluation | 2 | 2020 | 297 | 0.170 |
Why?
|
Personnel Staffing and Scheduling | 1 | 2020 | 93 | 0.170 |
Why?
|
Hyperparathyroidism, Secondary | 1 | 1999 | 70 | 0.170 |
Why?
|
Infection Control | 1 | 2020 | 115 | 0.170 |
Why?
|
Interviews as Topic | 1 | 2020 | 319 | 0.170 |
Why?
|
User-Computer Interface | 1 | 2020 | 185 | 0.170 |
Why?
|
Neutrophils | 1 | 2020 | 307 | 0.170 |
Why?
|
Cystadenoma, Serous | 2 | 2010 | 15 | 0.170 |
Why?
|
Medical Oncology | 1 | 2022 | 359 | 0.170 |
Why?
|
Asthma | 1 | 2007 | 955 | 0.170 |
Why?
|
Glucuronosyltransferase | 1 | 2020 | 184 | 0.170 |
Why?
|
Interinstitutional Relations | 1 | 2018 | 28 | 0.160 |
Why?
|
Triage | 1 | 2019 | 108 | 0.160 |
Why?
|
Abdominal Neoplasms | 1 | 2018 | 39 | 0.160 |
Why?
|
Antineoplastic Agents, Immunological | 1 | 2020 | 185 | 0.160 |
Why?
|
Lymphocytes | 1 | 2020 | 464 | 0.160 |
Why?
|
Conversion to Open Surgery | 1 | 2018 | 11 | 0.160 |
Why?
|
Rare Diseases | 1 | 2018 | 59 | 0.160 |
Why?
|
Organoids | 1 | 2018 | 61 | 0.160 |
Why?
|
Thoracic Neoplasms | 1 | 2018 | 64 | 0.160 |
Why?
|
Thorax | 1 | 2018 | 75 | 0.160 |
Why?
|
Mesenteric Veins | 1 | 2017 | 34 | 0.160 |
Why?
|
Lung Neoplasms | 2 | 2021 | 2262 | 0.160 |
Why?
|
Macrophages | 1 | 2001 | 554 | 0.150 |
Why?
|
Radiography, Thoracic | 1 | 2019 | 320 | 0.150 |
Why?
|
Treatment Failure | 2 | 2012 | 285 | 0.150 |
Why?
|
Cooperative Behavior | 1 | 2018 | 174 | 0.150 |
Why?
|
Pediatrics | 1 | 2001 | 344 | 0.140 |
Why?
|
Vascular Surgical Procedures | 1 | 2017 | 148 | 0.140 |
Why?
|
Cohort Studies | 6 | 2020 | 2767 | 0.140 |
Why?
|
Biomarkers, Tumor | 3 | 2020 | 1464 | 0.140 |
Why?
|
Psoas Muscles | 1 | 2015 | 2 | 0.140 |
Why?
|
Heart Arrest | 1 | 2019 | 265 | 0.140 |
Why?
|
Kidney Diseases | 1 | 1999 | 418 | 0.140 |
Why?
|
Minimally Invasive Surgical Procedures | 2 | 2020 | 237 | 0.140 |
Why?
|
Decision Support Techniques | 1 | 2017 | 160 | 0.130 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2020 | 930 | 0.130 |
Why?
|
Sensitivity and Specificity | 2 | 2013 | 1991 | 0.130 |
Why?
|
Kidney Neoplasms | 1 | 2020 | 621 | 0.130 |
Why?
|
Liposarcoma, Myxoid | 1 | 2014 | 3 | 0.130 |
Why?
|
Decision Making | 1 | 2020 | 642 | 0.130 |
Why?
|
Recurrence | 2 | 2012 | 1139 | 0.130 |
Why?
|
Liver | 2 | 2017 | 1230 | 0.120 |
Why?
|
Fatigue | 1 | 2015 | 174 | 0.120 |
Why?
|
Proportional Hazards Models | 4 | 2020 | 859 | 0.120 |
Why?
|
Teaching | 2 | 2013 | 147 | 0.120 |
Why?
|
Common Bile Duct Neoplasms | 1 | 2014 | 6 | 0.120 |
Why?
|
Duodenal Neoplasms | 1 | 2014 | 19 | 0.120 |
Why?
|
Positron-Emission Tomography | 2 | 2020 | 329 | 0.120 |
Why?
|
Age Factors | 4 | 2020 | 1851 | 0.120 |
Why?
|
Registries | 4 | 2018 | 702 | 0.110 |
Why?
|
Precision Medicine | 1 | 2017 | 395 | 0.110 |
Why?
|
Awards and Prizes | 1 | 2013 | 36 | 0.110 |
Why?
|
Tumor Burden | 1 | 2014 | 289 | 0.110 |
Why?
|
Gastric Mucosa | 1 | 2012 | 66 | 0.110 |
Why?
|
Multivariate Analysis | 4 | 2016 | 999 | 0.110 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 2438 | 0.110 |
Why?
|
Safety | 1 | 2013 | 152 | 0.110 |
Why?
|
Cholangitis | 1 | 2012 | 19 | 0.110 |
Why?
|
Proto-Oncogene Proteins c-kit | 2 | 2014 | 79 | 0.110 |
Why?
|
Choledocholithiasis | 1 | 2012 | 12 | 0.110 |
Why?
|
Duodenal Diseases | 1 | 2012 | 24 | 0.110 |
Why?
|
Kaplan-Meier Estimate | 3 | 2021 | 860 | 0.100 |
Why?
|
Genomics | 1 | 2017 | 720 | 0.100 |
Why?
|
Leadership | 1 | 2013 | 134 | 0.100 |
Why?
|
Diverticulum | 1 | 2012 | 44 | 0.100 |
Why?
|
Histocytochemistry | 1 | 2011 | 130 | 0.100 |
Why?
|
Radiography, Abdominal | 1 | 2011 | 71 | 0.100 |
Why?
|
Microscopy | 1 | 2011 | 87 | 0.100 |
Why?
|
Feasibility Studies | 1 | 2013 | 751 | 0.100 |
Why?
|
Cystadenoma, Mucinous | 1 | 2010 | 7 | 0.100 |
Why?
|
Cystadenoma, Papillary | 1 | 2010 | 8 | 0.090 |
Why?
|
Bilirubin | 2 | 2001 | 125 | 0.090 |
Why?
|
Combined Modality Therapy | 2 | 2014 | 1686 | 0.090 |
Why?
|
Cystadenocarcinoma, Serous | 1 | 2010 | 45 | 0.090 |
Why?
|
Gadolinium | 2 | 2001 | 103 | 0.090 |
Why?
|
ROC Curve | 3 | 2019 | 752 | 0.090 |
Why?
|
Cytoreduction Surgical Procedures | 2 | 2021 | 73 | 0.090 |
Why?
|
Incidence | 3 | 2022 | 1577 | 0.090 |
Why?
|
Phenotype | 3 | 2007 | 2378 | 0.090 |
Why?
|
Bile Duct Diseases | 1 | 2009 | 22 | 0.090 |
Why?
|
Endoscopy | 1 | 2012 | 332 | 0.090 |
Why?
|
Health Care Surveys | 1 | 2010 | 278 | 0.090 |
Why?
|
Lymphatic Metastasis | 2 | 2014 | 486 | 0.080 |
Why?
|
Feedback | 1 | 2009 | 133 | 0.080 |
Why?
|
Digestive System Surgical Procedures | 1 | 2010 | 120 | 0.080 |
Why?
|
Leucovorin | 2 | 2020 | 218 | 0.080 |
Why?
|
Barrett Esophagus | 1 | 2009 | 93 | 0.080 |
Why?
|
Students, Medical | 1 | 2013 | 384 | 0.080 |
Why?
|
Patient Readmission | 3 | 2016 | 329 | 0.080 |
Why?
|
Rats, Sprague-Dawley | 2 | 2001 | 1219 | 0.080 |
Why?
|
Academic Medical Centers | 1 | 2010 | 379 | 0.080 |
Why?
|
Histiocytes | 1 | 2007 | 22 | 0.070 |
Why?
|
Drug Therapy, Combination | 1 | 2009 | 894 | 0.070 |
Why?
|
Fluorouracil | 2 | 2020 | 556 | 0.070 |
Why?
|
Diagnosis, Differential | 1 | 2011 | 1565 | 0.070 |
Why?
|
Sclerosis | 1 | 2007 | 28 | 0.070 |
Why?
|
Palliative Care | 2 | 2020 | 257 | 0.070 |
Why?
|
Orbit | 1 | 2007 | 37 | 0.070 |
Why?
|
Adenoma, Islet Cell | 1 | 2006 | 28 | 0.070 |
Why?
|
Plasma Cells | 1 | 2007 | 80 | 0.070 |
Why?
|
Time Factors | 2 | 2017 | 5210 | 0.070 |
Why?
|
Gallbladder Neoplasms | 1 | 2006 | 22 | 0.070 |
Why?
|
Age of Onset | 1 | 2007 | 310 | 0.070 |
Why?
|
Frozen Sections | 1 | 2005 | 48 | 0.070 |
Why?
|
Young Adult | 4 | 2020 | 5976 | 0.060 |
Why?
|
Autoimmune Diseases | 1 | 2007 | 241 | 0.060 |
Why?
|
Infant, Newborn | 2 | 2001 | 2379 | 0.060 |
Why?
|
Practice Patterns, Physicians' | 1 | 2010 | 582 | 0.060 |
Why?
|
Frail Elderly | 2 | 2015 | 71 | 0.060 |
Why?
|
Logistic Models | 2 | 2020 | 1186 | 0.060 |
Why?
|
Rats | 2 | 2001 | 3990 | 0.060 |
Why?
|
Lymph Nodes | 2 | 2018 | 533 | 0.060 |
Why?
|
Immunoenzyme Techniques | 2 | 2001 | 303 | 0.060 |
Why?
|
Disease Models, Animal | 2 | 2001 | 2232 | 0.060 |
Why?
|
Microwaves | 1 | 2023 | 34 | 0.060 |
Why?
|
Adenoma | 1 | 2005 | 235 | 0.060 |
Why?
|
Cell Cycle Proteins | 1 | 2006 | 388 | 0.060 |
Why?
|
Illinois | 2 | 2014 | 462 | 0.060 |
Why?
|
Pilot Projects | 2 | 2017 | 839 | 0.060 |
Why?
|
Duodenum | 2 | 2014 | 100 | 0.050 |
Why?
|
Bile | 1 | 2022 | 57 | 0.050 |
Why?
|
Learning Curve | 1 | 2022 | 18 | 0.050 |
Why?
|
Helsinki Declaration | 1 | 2001 | 4 | 0.050 |
Why?
|
Ki-67 Antigen | 2 | 2014 | 64 | 0.050 |
Why?
|
Body Fluids | 1 | 2001 | 36 | 0.050 |
Why?
|
Cancer Pain | 1 | 2020 | 3 | 0.050 |
Why?
|
Genetic Predisposition to Disease | 1 | 2009 | 2271 | 0.050 |
Why?
|
Documentation | 1 | 2001 | 98 | 0.050 |
Why?
|
Bile Ducts | 1 | 2000 | 59 | 0.050 |
Why?
|
Immunoradiometric Assay | 1 | 1999 | 2 | 0.050 |
Why?
|
Uncertainty | 1 | 2020 | 71 | 0.050 |
Why?
|
Lymphocyte Count | 1 | 2020 | 94 | 0.050 |
Why?
|
Chi-Square Distribution | 1 | 2001 | 364 | 0.050 |
Why?
|
Hyperplasia | 1 | 2000 | 148 | 0.050 |
Why?
|
Forearm | 1 | 1999 | 32 | 0.050 |
Why?
|
Morbidity | 1 | 2020 | 148 | 0.050 |
Why?
|
Chemical and Drug Induced Liver Injury | 1 | 2000 | 69 | 0.040 |
Why?
|
Trachea | 1 | 2001 | 293 | 0.040 |
Why?
|
Reproducibility of Results | 1 | 2006 | 2705 | 0.040 |
Why?
|
Lower Extremity | 1 | 2020 | 84 | 0.040 |
Why?
|
Intestinal Obstruction | 1 | 2020 | 88 | 0.040 |
Why?
|
Regression Analysis | 1 | 2001 | 596 | 0.040 |
Why?
|
Fibrosis | 1 | 2000 | 203 | 0.040 |
Why?
|
Ultrasonography, Prenatal | 1 | 2000 | 152 | 0.040 |
Why?
|
Vital Signs | 1 | 2019 | 38 | 0.040 |
Why?
|
Flow Cytometry | 1 | 2001 | 679 | 0.040 |
Why?
|
Body Weight | 1 | 2000 | 459 | 0.040 |
Why?
|
Collagen | 1 | 2000 | 269 | 0.040 |
Why?
|
Parathyroid Hormone | 1 | 1999 | 218 | 0.040 |
Why?
|
Transplantation, Autologous | 1 | 1999 | 331 | 0.040 |
Why?
|
Retroperitoneal Space | 1 | 2018 | 38 | 0.040 |
Why?
|
Perioperative Period | 1 | 2018 | 25 | 0.040 |
Why?
|
Molecular Targeted Therapy | 1 | 2020 | 266 | 0.040 |
Why?
|
Pregnancy Outcome | 1 | 2000 | 247 | 0.040 |
Why?
|
Medical Staff, Hospital | 2 | 2009 | 107 | 0.040 |
Why?
|
Liver Diseases | 1 | 2000 | 238 | 0.040 |
Why?
|
Nephrectomy | 1 | 2020 | 294 | 0.040 |
Why?
|
Anti-Inflammatory Agents | 1 | 2001 | 339 | 0.040 |
Why?
|
Intention to Treat Analysis | 1 | 2018 | 72 | 0.040 |
Why?
|
Odds Ratio | 1 | 2020 | 678 | 0.040 |
Why?
|
Chemoradiotherapy, Adjuvant | 1 | 2018 | 35 | 0.040 |
Why?
|
Filgrastim | 1 | 2017 | 56 | 0.040 |
Why?
|
Pneumonectomy | 1 | 2000 | 196 | 0.040 |
Why?
|
Wound Healing | 1 | 2020 | 344 | 0.040 |
Why?
|
Curriculum | 1 | 2022 | 539 | 0.040 |
Why?
|
Health Services Research | 1 | 2018 | 136 | 0.040 |
Why?
|
Organoplatinum Compounds | 1 | 2017 | 94 | 0.040 |
Why?
|
Renal Dialysis | 1 | 2020 | 355 | 0.040 |
Why?
|
Postoperative Hemorrhage | 1 | 2017 | 46 | 0.040 |
Why?
|
Animals | 4 | 2018 | 26582 | 0.040 |
Why?
|
Operative Time | 1 | 2017 | 127 | 0.040 |
Why?
|
Algorithms | 1 | 2005 | 1830 | 0.040 |
Why?
|
Bone Neoplasms | 1 | 2020 | 322 | 0.040 |
Why?
|
Health Care Costs | 1 | 2019 | 238 | 0.040 |
Why?
|
Blood Loss, Surgical | 1 | 2017 | 112 | 0.040 |
Why?
|
Analysis of Variance | 2 | 2014 | 912 | 0.040 |
Why?
|
Tumor Microenvironment | 1 | 2020 | 418 | 0.040 |
Why?
|
Blood Transfusion | 1 | 2017 | 157 | 0.040 |
Why?
|
Camptothecin | 1 | 2017 | 189 | 0.040 |
Why?
|
Shock, Septic | 1 | 2017 | 102 | 0.040 |
Why?
|
Chronic Disease | 1 | 2000 | 971 | 0.040 |
Why?
|
Postoperative Care | 1 | 2017 | 221 | 0.040 |
Why?
|
Body Mass Index | 1 | 2020 | 770 | 0.040 |
Why?
|
Skin | 1 | 1999 | 554 | 0.040 |
Why?
|
Pregnancy | 2 | 2001 | 2894 | 0.040 |
Why?
|
Graft Survival | 1 | 1999 | 884 | 0.030 |
Why?
|
Epithelial Cells | 1 | 2000 | 669 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2017 | 916 | 0.030 |
Why?
|
Electronic Health Records | 1 | 2019 | 319 | 0.030 |
Why?
|
Disease Progression | 1 | 2000 | 1531 | 0.030 |
Why?
|
Polyethylene Glycols | 1 | 2017 | 363 | 0.030 |
Why?
|
Reoperation | 1 | 2017 | 597 | 0.030 |
Why?
|
Keratin-19 | 1 | 2014 | 9 | 0.030 |
Why?
|
Contrast Media | 1 | 2000 | 1078 | 0.030 |
Why?
|
Genotype | 1 | 2020 | 1851 | 0.030 |
Why?
|
Adolescent | 2 | 2020 | 8981 | 0.030 |
Why?
|
Inhibitor of Apoptosis Proteins | 1 | 2014 | 33 | 0.030 |
Why?
|
Inflammation | 1 | 2020 | 920 | 0.030 |
Why?
|
Area Under Curve | 1 | 2015 | 334 | 0.030 |
Why?
|
Organ Size | 1 | 2015 | 364 | 0.030 |
Why?
|
Perioperative Care | 1 | 2016 | 161 | 0.030 |
Why?
|
Lung | 1 | 2001 | 1170 | 0.030 |
Why?
|
Antibodies, Monoclonal | 1 | 2001 | 1376 | 0.030 |
Why?
|
Duodenoscopy | 1 | 2014 | 8 | 0.030 |
Why?
|
Postoperative Period | 1 | 2014 | 303 | 0.030 |
Why?
|
Child, Preschool | 1 | 2001 | 3612 | 0.030 |
Why?
|
Self Report | 1 | 2015 | 288 | 0.030 |
Why?
|
Neoplasms | 1 | 2009 | 2898 | 0.030 |
Why?
|
Biomarkers | 1 | 2020 | 1718 | 0.030 |
Why?
|
Hospitalization | 1 | 2019 | 849 | 0.030 |
Why?
|
Competency-Based Education | 1 | 2013 | 35 | 0.030 |
Why?
|
Kidney Transplantation | 1 | 1999 | 849 | 0.030 |
Why?
|
Anastomosis, Roux-en-Y | 1 | 2012 | 26 | 0.030 |
Why?
|
Needs Assessment | 1 | 2013 | 154 | 0.030 |
Why?
|
Guidelines as Topic | 1 | 2013 | 162 | 0.030 |
Why?
|
Jejunum | 1 | 2012 | 79 | 0.030 |
Why?
|
Severity of Illness Index | 1 | 2017 | 1801 | 0.030 |
Why?
|
Career Choice | 1 | 2013 | 139 | 0.030 |
Why?
|
Education, Medical | 1 | 2013 | 233 | 0.020 |
Why?
|
Sex Factors | 1 | 2013 | 1054 | 0.020 |
Why?
|
Medical Records Systems, Computerized | 1 | 2009 | 40 | 0.020 |
Why?
|
Child | 1 | 2001 | 6927 | 0.020 |
Why?
|
Task Performance and Analysis | 1 | 2009 | 86 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2013 | 1056 | 0.020 |
Why?
|
Intestinal Mucosa | 1 | 2014 | 797 | 0.020 |
Why?
|
Cross-Sectional Studies | 1 | 2013 | 1621 | 0.020 |
Why?
|
Internet | 1 | 2009 | 312 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2006 | 30 | 0.020 |
Why?
|
Proliferating Cell Nuclear Antigen | 1 | 2006 | 66 | 0.020 |
Why?
|
Quality of Health Care | 1 | 2009 | 380 | 0.020 |
Why?
|
Cyclin D1 | 1 | 2006 | 83 | 0.020 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2006 | 74 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2006 | 189 | 0.020 |
Why?
|
Mice | 1 | 2018 | 11352 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2006 | 381 | 0.010 |
Why?
|
Neoplasm Invasiveness | 1 | 2005 | 552 | 0.010 |
Why?
|
Up-Regulation | 1 | 2006 | 712 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2006 | 1753 | 0.010 |
Why?
|
Ligation | 1 | 2001 | 51 | 0.010 |
Why?
|
Sheep | 1 | 2001 | 239 | 0.010 |
Why?
|
Blotting, Northern | 1 | 2001 | 256 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2006 | 1197 | 0.010 |
Why?
|
Pressure | 1 | 2001 | 165 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2001 | 307 | 0.010 |
Why?
|
Microscopy, Electron | 1 | 2001 | 503 | 0.010 |
Why?
|
Cell Division | 1 | 2001 | 696 | 0.010 |
Why?
|
RNA | 1 | 2001 | 560 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2001 | 1204 | 0.010 |
Why?
|